Market News & Trends
Aptar Digital Health Announces Acquisition of Healint to Reinforce Digital Health Portfolio & Drive Future Growth
Aptar Digital Health recently announced it has acquired Healint, a digital health company recognized for their virtual clinical studies, real-world evidence and patient registries platform,…
Polpharma Biologics’ Investigational Biosimilar Shows PK/PD Comparability to Inflammatory Bowel Disease Blockbuster Entyvio
Polpharma Biologics recently announced topline results demonstrating the pharmacokinetic (PK) and pharmacodynamic (PD) comparability of its biosimilar candidate PB016 to its reference drug, Entyvio (vedolizumab). Results…
Cresset Announces Global Collaboration With Enamine on New Virtual Screening Drug Discovery Technology
Cresset recently announced a collaboration with Enamine, the world’s leading provider of chemical building blocks and drug discovery services to develop innovative….
Eton Pharmaceuticals Awarded US Patent for Proprietary Hydrocortisone Oral Liquid Formulation
Eton Pharmaceuticals recently announced the United States Patent and Trademark Office (USPTO) has granted the company’s US Patent Application No. 18/113,458, which covers the….
Vaccinex Announces Multiple New Agreements for Access to ActivMAb Antigen Virus Technology
Vaccinex, Inc. recently announced it has entered into eight new antibody discovery agreements integrating use of its proprietary ActivMAb platform to select antibodies against difficult-to-drug…
Dyadic Advances Collaboration With Israel Institute for Biological Research Targeting Bio-Threats & Emerging Disease Solutions
Dyadic International, Inc. and Israel Institute for Biological Research (IIBR) recently announced it has advanced its collaboration with IIBR and its commercial arm Life Science…
XOMA Enters Agreement to Acquire Kinnate Biopharma
Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolio….
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease; Advances Program Into Late Research
Voyager Therapeutics, Inc. recently announced new data from its two preclinical programs targeting pathological tau for the treatment of Alzheimer’s disease. Data on VY-TAU01, Voyager’s…
Evonik Partners With University of Mainz to Commercialize New Class of PEG Lipids for Nucleic Acid Delivery
Evonik and the University of Mainz have signed a license agreement to commercialize randomized polyethylene glycols (rPEGs), a new class of PEGs. Evonik intends to use….
Monopar Receives Clearance to Proceed With First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers
Monopar Therapeutics Inc. recently announced it has received Human Research Ethics Committee (HREC) clearance in Australia to commence a Phase 1 dosimetry trial of its…
Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
Immuneering Corporation recently announced the US FDA granted Fast Track designation for its lead clinical-stage program, IMM-1-104, for the treatment of patients with pancreatic ductal…
Mestag Therapeutics Enlists Leading Cancer Biology & Immunology Advisors to Support Clinical Development of its Lead Oncology Program
Mestag Therapeutics recently announced the appointments of additional distinguished, world-leading advisors to guide the development of its lead program M300, a first-in-class antibody program designed…
OrphAI Therapeutics Receives Orphan Drug Designation for AIT-101 as a Treatment for Amyotrophic Lateral Sclerosis in the European Union
OrphAI Therapeutics Inc. recently announced it has received Orphan Drug Designation (ODD) in the European Union (EU) for the treatment of amyotrophic lateral sclerosis (ALS).…
Alvotech Announces Expected Global Market Entry Dates for Biosimilar to Stelara
Alvotech recently announced it has reached settlement agreements with Johnson & Johnson in Japan, Canada, and in the European Economic Area (EEA) for AVT04, a…
Selkirk Pharma Announces New APS Qualified Facility With Advanced Fill/Finish Capacity in Spokane, WA
Selkirk Pharma, Inc. recently announced the Aseptic Process Simulation (APS) qualification of its sterile manufacturing facility and newly available fill/finish capacity. This development marks a…
Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published
Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys…..
Petros Pharmaceuticals Enters AI Licensing Agreement With Leading Multi-Billion-Dollar Software Provider
Petros Pharmaceuticals, Inc. recently announced a new partnership with a leading, multi-billion-dollar AI software provider to adapt its technology for self-screening and other benefits as…
FOXO Technologies Announces Non-Binding Agreement for Potentially Transformative Merger With M2i Global
FOXO Technologies Inc. recently announced it has entered into a non-binding agreement for a proposed merger with M2i Global, Inc., which specializes in the development…
PathAI Announces Exclusive Collaboration With Roche Tissue Diagnostics to Advance AI-enabled Interpretation for Companion Diagnostics
PathAI, Inc. recently announced an expanded and exclusive relationship with Roche Tissue Diagnostics (RTD) that will bring AI-enabled interpretation to companion diagnostics. Building upon the success…
VantAI Enters $674-Million Collaboration With Bristol Myers Squibb to Accelerate Molecular Glue Drug Discovery Through Artificial Intelligence
Collaboration to leverage VantAI’s expertise in generative AI and geometric deep learning to identify molecular glues against targets of interest with an option to expand to additional programs….
